Teleflex (TFX) Valuation Check After Mixed Share Price Performance And High P/E Multiple

Teleflex stock at a glance after recent performance

Teleflex (TFX) has drawn fresh attention after a mixed run, with the share price showing a small 1 day gain, a loss over the past week, but a positive move over the past month.

Over a longer period, the stock shows a negative return over the past 3 months and over the past year. The company has reported annual revenue of US$1.99b and net income of US$58.53m, which offers useful context for investors tracking the name.

See our latest analysis for Teleflex.

At around US$113.61 per share, Teleflex’s recent 4.8% 30 day share price return sits against a weaker backdrop, with the 1 year total shareholder return down about 17%, suggesting momentum has been fading rather than building.

If you are reassessing your healthcare exposure after Teleflex’s weaker long term total shareholder returns, this could be a good moment to scout other opportunities in the sector. You could start by looking at our screen of 32 healthcare AI stocks.

So with Teleflex’s share price weaker over 1 and 3 years but the stock trading at about US$113.61, should you view this as an undervalued healthcare name, or has the market already priced in its future growth?

Most Popular Narrative: 12.1% Undervalued

Teleflex’s most followed valuation narrative pegs fair value at about $129.25 per share, compared with the last close at $113.61, which frames a measurable gap to watch.

Ongoing investment in pipeline innovation, R&D, and digital integration (e.g., bioresorbable scaffolds like Freesolve and connected, infection-reducing devices) are expected to drive revenue and margin expansion by supporting premium pricing and differentiation in regulated, consolidation-prone markets.

Read the complete narrative.

Want to see what is baked into that fair value gap? The narrative leans heavily on faster earnings, higher margins, and a future earnings multiple that assumes solid execution without stretching past sector norms. Curious how those moving parts fit together and what has to go right for the story to hold?

The model behind this narrative uses a discount rate of 8.94% and ties Teleflex’s projected cash generation to a future P/E that sits below many current Medical Equipment benchmarks, while still implying healthier profitability than recent history. It combines revenue growth assumptions with higher net profit margins to arrive at that $129.25 figure, then compares it to today’s share price to assess how much optimism is already reflected.

Result: Fair Value of $129.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the story could change quickly if weaknesses in key product lines like UroLift persist, or if the BIOTRONIK integration fails to deliver the expected margin benefits.

Find out about the key risks to this Teleflex narrative.

Another angle on Teleflex’s valuation

The most popular narrative suggests Teleflex looks about 12.1% undervalued at $113.61 per share, yet the current P/E of 85.8x tells a very different story. That is far above the US Medical Equipment industry at 27.6x, peers at 52.3x, and even the fair ratio of 40.5x implied by our model.

In practical terms, that gap means you are paying considerably more for each dollar of current earnings than both the wider industry and similar companies, while the fair ratio points to a level the market could eventually move toward. The question is whether future profit growth will justify staying at this richer multiple, or if the share price needs to do some catching down instead.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Feeling torn between the positive and cautious signals in this story? Act while the details are fresh, consider both perspectives, and see how our breakdown of 1 key reward and 2 important warning signs lines up with your own view.

Looking for more investment ideas?

If Teleflex has you rethinking your next move, do not stop here. Use this momentum to line up a few fresh ideas for your watchlist.

• Prioritise quality at a discount by scanning our list of 46 high quality undervalued stocks that pair solid fundamentals with pricing that may leave room for upside.
• Strengthen your income stream by checking out 14 dividend fortresses, focusing on companies with higher yields that could support regular cash returns.
• Build a core of resilient names by reviewing our 63 resilient stocks with low risk scores, highlighting businesses with lower risk scores that may offer a steadier ride.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com